1. Home
  2. RBOT vs LEXX Comparison

RBOT vs LEXX Comparison

Compare RBOT & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vicarious Surgical Inc.

RBOT

Vicarious Surgical Inc.

HOLD

Current Price

$2.13

Market Cap

17.9M

Sector

Health Care

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.77

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBOT
LEXX
Founded
2014
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.9M
18.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RBOT
LEXX
Price
$2.13
$0.77
Analyst Decision
Hold
Strong Buy
Analyst Count
2
1
Target Price
$7.00
$1.50
AVG Volume (30 Days)
161.6K
217.4K
Earning Date
03-16-2026
01-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$522,000.00
Revenue This Year
N/A
$13.35
Revenue Next Year
N/A
$78.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5.05
52 Week Low
$1.81
$0.46
52 Week High
$16.35
$1.91

Technical Indicators

Market Signals
Indicator
RBOT
LEXX
Relative Strength Index (RSI) 39.07 47.52
Support Level $2.02 $0.71
Resistance Level $2.30 $0.80
Average True Range (ATR) 0.23 0.07
MACD -0.03 0.01
Stochastic Oscillator 12.24 44.14

Price Performance

Historical Comparison
RBOT
LEXX

About RBOT Vicarious Surgical Inc.

Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: